Thus, the complex effects of clusterin shown by the Hartl lab in Parkinson’s disease expand to Alzheimer’s disease (Yuste-Checa et al. 2021, 2022). This evidence concerns the gene CLU and early-onset autosomal dominant Alzheimer disease.